




TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/787,018
		Filing Date	February 24, 2004
		First Named Inventor	Gosling, Jennifa
		Art Unit	Not yet known
		Examiner Name	Not yet known
Total Number of Pages in This Submission		Attorney Docket Number	019934-000723US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard, copies of two references
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Aussenhus Reg. No. 42,271
Signature	
Date	April 30, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Nicole Wartell		
Signature		Date	April 30, 2004



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 019934-000723US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On April 30, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: 

Nicole Wartell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gosling et al.

Application No.: 10/787,018

Filed: February 24, 2004

For: Chemokine Receptor

Examiner: Not yet known

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner.

Applicants also wish to make the Examiner aware of the following co-pending patent applications:

<u>U.S. Patent App. No.</u>	<u>Filing date</u>	<u>Applicant</u>	<u>Attorney Docket No.</u>
09/686,020	10/10/2000	Gosling et al.	019934-000710US
09/721,341	11/21/2000	Gosling et al.	019934-000711US
09/686,019	10/10/2000	Gosling et al.	019934-000720US
09/721,495	11/21/2000	Gosling et al.	019934-000721US


This application is a continuation of and relies upon U.S. Patent Application No. 09/721,495 (Attorney Docket No. 019934-000721US) for an earlier effective filing date under 35 U.S.C. §120. In accordance with 37 CFR §1.98(d), copies of those references and copies of the co-pending applications that have been previously submitted to or cited by the Office in the parent application are not enclosed. Copies of references C11 and C22 are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321
SLA:nmb
60142884 v1



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
Application Number			10/787,018		
Filing Date			02-24-2004		
First Named Inventor			Gosling, Jennifa		
Art Unit			Not Yet known		
Examiner Name			Not Yet known		
Sheet	1	of	4	Attorney Docket Number	019934-000723US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-5,932,445	8-03-1999	Lal et al.	
	A2	US-6,110,695	8-29-2000	Gunn et al.	
	A3	US-2001/0016336 A1	8-23-2001	Ellis	
	A4	U.S. Patent Application No. 09/686,020		Gosling et al.	
	A5	U.S. Patent Application No. 09/721,341		Gosling et al.	
	A6	U.S. Patent Application No. 09/686,019		Gosling et al.	
	A7	U.S. Patent Application No. 09/721,495		Gosling et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	EP	0 899 332	A2	03-03-1999	Smith Kline Beecham		<input type="checkbox"/>
	B2	PCT	WO 99/24463	A2	05-20-1999	Incyte Pharmaceuticals, Inc.		<input type="checkbox"/>
	B3	PCT	WO 99/33876	A1	07-08-1999	Asahi Kasei Kogyo Kabushiki		<input type="checkbox"/>
	B4	PCT	WO 99/52945	A2	10-21-1999	Millenium Pharmaceuticals, Inc.		<input type="checkbox"/>
	B5	PCT	WO 00/26369	A1	05-11-2000	Chiron Corporation		<input type="checkbox"/>
	B6	PCT	WO 00/64941	A2	11-02-2000	Curagen Corporation		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
 60142884 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/787,018	
			Filing Date	02-24-2004	
			First Named Inventor	Gosling, Jennifa	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	2	of	4	Attorney Docket Number	019934-000723US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	DATABASE EMBL Accession No. Q9NPB9; 1 October 2000	
	C2	DATABASE EMBL Accession No. Y30125; 14 October 1999	
	C3	GenBank Accession Number AA215577; August 13, 1997	
	C4	GenBank Accession Number AF233281; May 22, 2000	
	C5	GenBank Accession Number AI131555; October 26, 1998	
	C6	GenBank Accession Number AI769466; June 28, 1999	
	C7	GenBank Accession Number AR003970; December 10, 1998	
	C8	GenBank Accession Number AW190975; November 22, 1999	
	C9	GenBank Accession Number E12852; June 24, 1998	
	C10	GenBank Accession Number H67224; October 27, 1995	
<i>/</i>	C11	BAGGIOLINI, M. "Chemokines in pathology and medicine." Journal Internal Medicine, 2001, pp. 91-104, Vol. 250.	
	C12	BORK, PEER, et al; Go hunting in sequence databases but watch out for the traps; <i>Trends in Genetics</i> ; October 1996; pp. 425-427; Vol. 12, No. 10	
	C13	BORK, PEER; Powers and Pitfalls in Sequence Analysis: The 70% Hurdle; <i>Genome Research</i> ; 2000; pp. 398-400; Vol. 10	
	C14	BRENNER, Steven E.; Errors in genome annotation; <i>Trends in Genetics</i> ; April 1999; pp. 132-133; Vol. 15, No. 4	
	C15	DAIRAGHI, DANIEL J.;, et al. Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength; The Journal of Biological Chemistry; November 7, 1997; pp. 28206-28209; Volume 272, No. 45	
	C16	DAIRAGHI, DANIEL J. et al.; HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8; The Journal of Biological Chemistry; July 30, 1999; pp. 21569-21574; Volume 274, No. 31	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

* Received only 2 NPL.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/787,018	
			Filing Date	02-24-2004	
			First Named Inventor	Gosling, Jennifa	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	3	of	4	Attorney Docket Number	019934-000723US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C17	DOERKS, TOBIAS, et al.; Protein annotation: detective work for function prediction; <i>Trends in Genetics</i> ; June 1998; pp. 248-250; Vol. 14, No. 6	
	C18	GOSLING, JENNIFA, et al; Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell-and T Cell-Active Chemokines Including ELC, SLC, and TECK; <i>The Journal of Immunology</i> ; 2000; pp. 2851-2856	
	C19	KHOJA, HAMIDUDDIN, et al.; Cloning of CCRL1, an orphan seven transmembrane receptor related to chemokine receptors, expressed abundantly in the heart; <i>Gene</i> ; 2000; pp. 229-238; Volume 246	
	C20	HULME, E.C., editor; Receptor-Ligand Interactions A Practical Approach; 1992; Preface, Table of Contents, Chapters 6,7, 8 and 9; pp. viii-xv and 213-263; IRL Press at Oxford University Press Inc., New York, New York	
	C21	MATSUOKA, ICHIRO et al.; Identification of Novel Members of G-Protein Coupled Receptor Superfamily Expressed in Bovine Taste Tissue; <i>Biochemical and Biophysical Research Communications</i> ; July 15, 1993; pp. 504-511; volume 194, No. 1	
	C22	MURPHY, P. "International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature" <i>Pharmacological Reviews</i> , 2002, pp. 227-229, Vol. 54, USA.	
	C23	NGO, J. THOMAS, et al; Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox; <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. LeGrand, Editors; 1994; pp. 491-495; Birkhauser, Boston	
	C24	O'DOWD, BRIAN F., et al.; A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain; <i>FEBS Letters</i> 1996; pp 325-329	
	C25	SCHWEICKART, VICKI L. et al.; CCR11 Is a Functional Receptor for the Monocyte Chemoattractant Protein Family of Chemokines; <i>The Journal of Biological Chemistry</i> ; March 31, 2000; pp. 9550-9556; volume 275, No. 13.	
	C26	SISSORS, DANIEL L., et al.; A Homogeneous Receptor Binding Assay for HTS on FlashPlate® Plus; NEN® Life Science Products, Inc.; 1999; pp. 1-7	
	C27	SKOLNICK, JEFFREY, et al; From gene to protein structure and function: novel applications of computational approaches in the genomic era; <i>Trends in Biotech</i> ; 2000; pp. 34-39; Vol. 18, No. 1	
	C28	SMITH, TEMPLE F., et al; The challenges of genome sequence annotation or "The devil is in the details"; <i>Nature Biotechnology</i> ; November 1997; pp. 1222-1223; Vol. 15	
	C29	TOWNSON, JANE R., et al.; Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3β/mCCL19: comparison to human CCX-CKR; <i>Eur. J. Immunol</i> ; 2002; pp. 1230-1241; Volume 32	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	10/787,018
				<i>Filing Date</i>	02-24-2004
				<i>First Named Inventor</i>	Gosling, Jennifa
				<i>Art Unit</i>	Not yet known
				<i>Examiner Name</i>	Not yet known
Sheet	4	of	4	<i>Attorney Docket Number</i>	019934-000723US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C30	Wells, James A.; Additivity of Mutational Effects in Proteins; <i>Biochemistry</i> ; September 18, 1990; pp. 8509-8517; Vol. Vol. 29, No. 37	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.